These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35087084)

  • 1. Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose.
    Capeding MR; Tadesse BT; Sil A; Alberto E; Kim DR; Park EL; Park JY; Yang JS; Eluru JR; Jo SK; Kim H; Yang SY; Ryu JH; Park H; Shin JH; Lee Y; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    NPJ Vaccines; 2022 Jan; 7(1):12. PubMed ID: 35087084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
    Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
    Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
    Vadrevu KM; Raju D; Rani S; Reddy S; Sarangi V; Ella R; Javvaji B; Mahantshetty NS; Battu S; Levine MM
    Vaccine; 2021 Oct; 39(45):6682-6690. PubMed ID: 34625288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.
    Carlos JC; Tadesse BT; Borja-Tabora C; Alberto E; Ylade MC; Sil A; Kim DR; Ahn HS; Yang JS; Lee JY; Kim MS; Park J; Kwon SY; Kim H; Yang SY; Ryu JH; Park H; Shin JH; Lee Y; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Reg Health West Pac; 2022 Jul; 24():100484. PubMed ID: 35664443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.
    Chaudhary S; Shah GS; Bhatta NK; Poudel P; Rai B; Uranw S; Tripathi PM; Khanal B; Ghimire A; Rai N; Gupta BP; Vemula S; Wartel TA; Sahastrabuddhe S; Saluja T
    Hum Vaccin Immunother; 2023 Dec; 19(1):2203634. PubMed ID: 37128723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine.
    Medise BE; Soedjatmiko S; Rengganis I; Gunardi H; Sekartini R; Koesno S; Satari HI; Hadinegoro SR; Yang JS; Excler JL; Sahastrabuddhe S; Puspita M; Sari RM; Bachtiar NS
    PLoS One; 2019; 14(2):e0211784. PubMed ID: 30759132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study.
    Capeding MR; Sil A; Tadesse BT; Saluja T; Teshome S; Alberto E; Kim DR; Park EL; Park JY; Yang JS; Chinaworapong S; Park J; Jo SK; Chon Y; Yang SY; Ryu JH; Cheong I; Shim KY; Lee Y; Kim H; Lynch JA; Kim JH; Excler JL; Wartel TA; Sahastrabuddhe S
    EClinicalMedicine; 2020 Oct; 27():100540. PubMed ID: 33150320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.
    Capeding MR; Alberto E; Sil A; Saluja T; Teshome S; Kim DR; Park JY; Yang JS; Chinaworapong S; Park J; Jo SK; Chon Y; Yang SY; Ham DS; Ryu JH; Lynch J; Kim JH; Kim H; Excler JL; Wartel TA; Sahastrabuddhe S
    Vaccine; 2020 Jun; 38(28):4476-4483. PubMed ID: 31585725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
    Capeding MR; Teshome S; Saluja T; Syed KA; Kim DR; Park JY; Yang JS; Kim YH; Park J; Jo SK; Chon Y; Kothari S; Yang SY; Ham DS; Ryu JH; Hwang HS; Mun JH; Lynch JA; Kim JH; Kim H; Excler JL; Sahastrabuddhe S
    Vaccine; 2018 Jun; 36(26):3794-3801. PubMed ID: 29776750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Persistence of Immunogenicity After Primary Vaccination and Response to Booster Vaccination With Typhoid Conjugate Vaccine: Results of a Phase IV Extension Study.
    Kandulna AK; Uttam KG; Sharma S; Kumar MR; Prasad KS; Goyal VK; Jangid SK; Daultani P; Mittal R; Maithal K
    Indian Pediatr; 2022 May; 59(5):388-392. PubMed ID: 35348124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine.
    Medise BE; Soedjatmiko S; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Wirahmadi A; Puspita M; Sari RM; Yang JS; Sil A; Sahastrabuddhe S; Bachtiar NS
    Int J Infect Dis; 2020 Apr; 93():102-107. PubMed ID: 32004693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers.
    Tamrakar D; Poudel P; Thapa P; Singh S; Khadgi A; Thapa S; Tamrakar R; Shrestha A; Madhup S; Rai GK; Gupta BP; Saluja T; Sahastrabuddhe S; Shrestha R
    Hum Vaccin Immunother; 2024 Dec; 20(1):2301631. PubMed ID: 38189360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
    Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of reconstitution of an Haemophilus influenzae type b-tentanus toxoid conjugate (PRP-T) vaccine on the immune responses to a diphtheria-tetanus-whole cell pertussis (DTwP) vaccine: a five-year follow-up.
    Hoppenbrouwers K; Roelants M; Ethevenaux C; Vandermeulen C; Knops J; Desmyter J
    Vaccine; 1999 Jun; 17(20-21):2588-98. PubMed ID: 10418907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of Vi-diphtheria toxoid typhoid conjugate vaccine among children below 2 years: a systematic review and meta-analysis.
    Mohamed Taha A; Abouelmagd K; Mahmoud AM; Elkasaby MH; Nguyen D; Ahmed R; Patel P; Bonilla-Aldana DK; Luna C; Rodriguez-Morales AJ
    Front Microbiol; 2024; 15():1385834. PubMed ID: 38646637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT).
    Lee EY; Park JY; Kim DR; Song M; Sahastrabuddhe S; Kim H; Chon Y; Yang JS
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008171. PubMed ID: 32203521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV.
    Gajdos V; Vidor E; Richard P; Tran C; Sadorge C
    Vaccine; 2015 Jul; 33(32):3988-96. PubMed ID: 26087294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity.
    Koesnoe S; Medise BE; Rengganis I; Hadinegoro SR; Puspita M; Sari RM; Yang JS; Sahastrabuddhe S; Soedjatmiko ; Gunardi H; Sekartini R; Wirahmadi A; Kekalih A; Mukhi S; Satari HI; Bachtiar NS
    Trop Dis Travel Med Vaccines; 2024 Feb; 10(1):3. PubMed ID: 38297337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine.
    An SJ; Yoon YK; Kothari S; Kim DR; Kim JA; Kothari N; Lee E; Park TH; Carbis R
    Vaccine; 2012 Feb; 30(6):1023-8. PubMed ID: 22192846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.